Gene therapy for congenital heart block
The rhythmic pumping function of the heart muscle is mediated by a built-in electrical system. In congenital complete heart block (CCHB) this system malfunctions due to structural defects or autoimmunity, causing abnormal propagation of electrical impulses in the heart. CCHB is diagnosed in utero, at birth or during the first months of life and is associated with bradycardia. The only treatment is the implantation of a permanent pacemaker. The ERC-based RescuePace project proposes a gene therapy approach to treat CCHB. The procedure entails the administration of an adenoviral vector that expresses ion channels in the heart to increase the heart rate and allow the patient to survive until birth, when a pacemaker can be implanted.
Fields of science
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Call for proposalSee other projects for this call
Funding SchemeERC-POC - Proof of Concept Grant
See on map